Getting It Right: How Early Engagements with CDMOs Add Value to Small Biotechs

Marwood Group estimates that there are more than 500 CDMOs globally and with more 45 large pharma and big biotech in the $10B+ Market Cap range, many emerging biotechs see themselves as small fish in a big pond when considering CDMO partners.  With the goal of getting life-changing medicines to patients in a timely, continuous fashion hovering in the background, early engagements with CDMOs can realize company goals faster but many biotechs lack the internal resources and/or expertise to identify the right partner.  This panel will highlight success stories and provide an in-depth review of questions to ask and what to look for, including the critical capabilities and an evaluation of CDMOs knowledge, when searching for a CDMO.